RxDoctor Payments Data

Amy Blevins, APRN

Family · Knoxville, TNNPI 1689247553

Payments from drug & device makers

$1,706in general payments, 2019–2025

Across 83 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$714
  • Scilex Pharmaceuticals Inc.$208
  • Collegium Pharmaceutical, Inc.$167
  • Penumbra, Inc.$150
  • Medtronic$134
  • Biodelivery Sciences International, Inc.$61
  • plus $272 from 11 others

What the payments were for

  • Food & beverage$1,706100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,706 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$224,174
Medicare patients
179
Services billed
3,962

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Potassium297$472,900
Lidocaine772$118,072
Clobetasol EmollientClobetasol Propionate/Emoll170$48,814
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen975$34,876
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen704$21,505
ZtlidoLidocaine21$18,073
MovantikNaloxegol Oxalate21$12,026
Xtampza ErOxycodone Myristate16$10,170
Clobetasol Propionate43$9,056
Oxycodone Hcl453$8,958
Gabapentin590$8,088
Diclofenac Sodium132$6,481
LinzessLinaclotide11$5,708
Naloxone Hcl74$4,465
Pregabalin152$3,499

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Scilex Pharmaceuticals Inc.Ztlido$208$18,07321 claims
Redhill Biopharma Inc.Movantik$16$12,02621 claims
Collegium Pharmaceutical, Inc.Xtampza Er$167$10,17016 claims
AbbVieLinzess$21$5,70811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.

Other family in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →